Array BioPharma
{{Infobox company
| name = Array BioPharma
| type = Subsidiary
| traded_as = {{NASDAQ was|ARRY}}
| industry = Oncology
Medication
| founded = {{start date and age|1998}}
| founder = {{ubl|Drs. Tony Piscopio|Kevin Koch|David Snitman|K.C. Nicolaou}}
| hq_location_city = Boulder, Colorado
| hq_location_country = United States
| revenue = $173.8 million (2018)
| parent = Pfizer
| website = {{URL|https://www.arraybiopharma.com/}}
}}
Array BioPharma is an American clinical stage, pharmaceutical company that focuses on oncology medication headquartered in Boulder, Colorado. The company is currently a subsidiary of Pfizer after being acquired for $11 billion in 2019.
History
In 1998, the company was founded by Drs. Tony Piscopio, Kevin Koch, David Snitman, and K.C. Nicolaou.{{Cite web|title=Co-Founder Of Array BioPharma, Inc. To Lead New Korean Out-Sourcing Chemistry Company|url=https://www.biospace.com/article/co-founder-of-array-biopharma-inc-to-lead-new-korean-out-sourcing-chemistry-company-/|access-date=2020-07-28|website=BioSpace|language=en-US}}
In November 2000, the company became a public company via an initial public offering.{{cite news | url=https://money.cnn.com/2000/11/17/deals/ipos/ | title=Array IPO up 17% | work=CNN | date=November 17, 2000}}
In June 2019, Pfizer acquired the company for approximately $11 billion.{{Cite web|title=Pfizer acquires Array BioPharma, valued at $11.4 billion|url=https://rappler.com/business/pfizer-acquisition-array-biopharma|access-date=2020-07-29|website=Rappler|date=18 June 2019 |language=en}}
Discovery of FDA Approved Small Molecules
- MEKTOVI (Binimetinib) - selective MEK inhibitor - Approved 2018, acquired by Pfizer
- TUKYSA (Tucatinib) - HER2 inhibitor - Approved 2020, owned by Seagen (Seattle Genetics)
- BRAFTOVI (Encorafenib) - BRAF inhibitor - Approved 2018, acquired by Pfizer
- KRAZATI (Adagrasib) - KRasG12C mutation inhibitor - Approved 2022, collaboration with Mirati Therapeutics
- KOSELUGO (Selumetinib) - MEK1/2 inhibitor - Approved 2020, licensed by Astrazeneca
- VITRAKVI (Larotrectinib) - TRK Inhibitor - Approved 2018, licensed by Loxo Oncology (Eli Lilly)
References
{{Reflist}}
{{Authority control}}
Category:1998 establishments in Colorado
Category:2000 initial public offerings
Category:2019 mergers and acquisitions
Category:American companies established in 1998
Category:Pharmaceutical companies established in 1998
Category:Biotechnology companies established in 1998
Category:Pharmaceutical companies of the United States
Category:Companies formerly listed on the Nasdaq
Category:Biotechnology companies of the United States
Category:Health care companies based in Colorado